Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf Conversion in New Liver Transplant Recipients
NCT03423225Phase 4Completed
- Start
- Mar 2016
- Primary completion
- Jul 2017
- Modality
- RNA-Targeting Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in Liver transplant rejection. Primary endpoint: Incidence rate of acute rejection reaction confirmed by biopsy at 24 weeks. Started Mar 2016; status: completed.
02
Drugs
tacrolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT03423225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423225.